“Three phase III studies being presented at the European Committee for Treatment Research in Multiple Sclerosis (ECTRIMS) congress demonstrate that treating MS with ocrelizumab reduces relapse rate and delay onset of disability progression compared to interferon beta-1a (Rebif®) in relapsing form
“Three phase III studies being presented at the European Committee for Treatment Research in Multiple Sclerosis (ECTRIMS) congress demonstrate that treating MS with ocrelizumab reduces relapse rate and delay onset of disability progression compared to interferon beta-1a (Rebif®) in relapsing form
このブックマークにはスターがありません。
最初のスターをつけてみよう！
Phase III studies show Roche's ocrelizumab reduces relapse rate, delays disability progression in MS patients
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／